⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VYGR News
Voyager Therapeutics, Inc. Common Stock
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
globenewswire.com
VYGR
Form 8-K
sec.gov
VYGR
Form 8-K
sec.gov
VYGR
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
globenewswire.com
VYGR
A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach
prnewswire.com
BIOA
CRSP
VRTX
VYGR
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
globenewswire.com
VYGR
Form 8-K
sec.gov
VYGR
Voyager Reports First Quarter 2026 Financial and Operating Results
globenewswire.com
VYGR
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
globenewswire.com
VYGR
Form 8-K
sec.gov
VYGR